These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 12898184)

  • 41. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
    Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
    Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
    J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B; Vega MI
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia.
    Seggewiss R; Ho AD; Kraemer A
    Ann Hematol; 2004 May; 83(5):316-8. PubMed ID: 15064861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequential development of histiocytic sarcoma and diffuse large b-cell lymphoma in a patient with a remote history of follicular lymphoma with genotypic evidence of a clonal relationship: a divergent (bilineal) neoplastic transformation of an indolent B-cell lymphoma in a single individual.
    Wang E; Papalas J; Hutchinson CB; Kulbacki E; Huang Q; Sebastian S; Rehder C; Silbermins D; Moore J; Datto M
    Am J Surg Pathol; 2011 Mar; 35(3):457-63. PubMed ID: 21317718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
    J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
    J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles.
    Almasri NM; Iturraspe JA; Braylan RC
    Arch Pathol Lab Med; 1998 Jun; 122(6):539-44. PubMed ID: 9625422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
    Kinoshita T; Nagai H; Murate T; Saito H
    J Clin Oncol; 1998 Dec; 16(12):3916. PubMed ID: 9850038
    [No Abstract]   [Full Text] [Related]  

  • 56. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
    Berinstein NL; Buckstein R; Imrie K; Spaner D; Mangel J; Tompkins K; Pennell N; Reis M; Pavlin P; Lima A; Couvadia A; Robinson J; Richardson P
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S14-7. PubMed ID: 11840156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
    J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas.
    Manazza AD; Bonello L; Pagano M; Chiusa L; Novero D; Stacchini A; Martini G; Vitolo U; Tarella C; Inghirami G; Palestro G; Chiarle R
    Am J Clin Pathol; 2005 Aug; 124(2):182-90. PubMed ID: 16040287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial.
    Witzens-Harig M; Reiz M; Heiss C; Benner A; Hensel M; Neben K; Dreger P; Kraemer A; Ho AD
    Ann Hematol; 2009 Jan; 88(1):51-7. PubMed ID: 18665360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.